Compare SYRE & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYRE | OPK |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 1.0B |
| IPO Year | 2016 | 1995 |
| Metric | SYRE | OPK |
|---|---|---|
| Price | $33.30 | $1.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $55.50 | $2.28 |
| AVG Volume (30 Days) | 745.7K | ★ 2.8M |
| Earning Date | 11-04-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $642,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.91 | $1.11 |
| 52 Week High | $35.31 | $2.04 |
| Indicator | SYRE | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 68.01 | 48.34 |
| Support Level | $33.51 | $1.28 |
| Resistance Level | $35.31 | $1.42 |
| Average True Range (ATR) | 1.81 | 0.05 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 76.82 | 50.32 |
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.